Despite recent pullbacks, exchange-traded funds in the biotech sector continue to outperform the market.The S&P 500 has lost 32% year to date. While the major biotech ETFs have faced resistance, their performance has been nowhere close to that experienced by the broader market indices. So far this year the SPDR Biotech ETF (XBI) and the iShares Nasdaq Biotechnology Fund (IBB) are down only 9.7% and 11.6%, respectively. The Biotech HOLDRS Trust (BBH) is actually up 0.3% year to date.
Biotech ETFs Show Resiliency
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.